These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33496513)

  • 21. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma.
    Bedrose S; Miller KC; Altameemi L; Ali MS; Nassar S; Garg N; Daher M; Eaton KD; Yorio JT; Daniel DB; Campbell M; Bible KC; Ryder M; Chintakuntlawar AV; Habra MA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
    Okuma Y; Nomura S; Sakakibara-Konishi J; Tsukita Y; Murakami S; Hosomi Y; Tambo Y; Kogure Y; Yoshioka H; Tamiya M; Ninomiya K; Iwama E
    Clin Lung Cancer; 2024 Jun; 25(4):389-394. PubMed ID: 38413246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors.
    Al-Toubah T; Schell MJ; Morse B; Haider M; Valone T; Strosberg J
    ESMO Open; 2024 Apr; 9(4):102386. PubMed ID: 38507897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
    Kawazoe A; Fukuoka S; Nakamura Y; Kuboki Y; Wakabayashi M; Nomura S; Mikamoto Y; Shima H; Fujishiro N; Higuchi T; Sato A; Kuwata T; Shitara K
    Lancet Oncol; 2020 Aug; 21(8):1057-1065. PubMed ID: 32589866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study.
    Shang X; Su H; Chen X; Wang Y; Wan X; Zhang Y; Jin Y; Feng F
    Int J Gynecol Cancer; 2024 Aug; 34(8):1203-1210. PubMed ID: 38658019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
    Harrington KJ; Kong A; Mach N; Chesney JA; Fernandez BC; Rischin D; Cohen EEW; Radcliffe HS; Gumuscu B; Cheng J; Snyder W; Siu LL
    Clin Cancer Res; 2020 Oct; 26(19):5153-5161. PubMed ID: 32669371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
    Motzer RJ; Choueiri TK; Hutson T; Young Rha S; Puente J; Lalani AA; Winquist E; Eto M; Basappa NS; Tannir NM; Vaishampayan U; Bjarnason GA; Oudard S; Grünwald V; Burgents J; Xie R; McKenzie J; Powles T
    Eur Urol; 2024 Jul; 86(1):4-9. PubMed ID: 38582713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Sun L; Cohen RB; Dimitrios Colevas A
    Oral Oncol; 2024 Nov; 158():106997. PubMed ID: 39159526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.
    Forster M; Brana I; Pousa AL; Doger B; Roxburgh P; Bajaj P; Peguero J; Krebs M; Carcereny E; Patel G; Mueller C; Brignone C; Triebel F
    Clin Cancer Res; 2024 Sep; 30(17):3726-3734. PubMed ID: 38995265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis.
    Tochigi M; Shigeta S; Shimada M; Miyahara S; Hasegawa-Minato J; Shibuya Y; Ishibashi M; Hashimoto C; Tokunaga H; Yaegashi N
    Tohoku J Exp Med; 2024 Feb; 262(2):85-95. PubMed ID: 38008437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lang Y; Dong D; Wu B
    Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
    Kawazoe A; Xu RH; García-Alfonso P; Passhak M; Teng HW; Shergill A; Gumus M; Qvortrup C; Stintzing S; Towns K; Kim TW; Shiu KK; Cundom J; Ananda S; Lebedinets A; Fu R; Jain R; Adelberg D; Heinemann V; Yoshino T; Elez E;
    J Clin Oncol; 2024 Aug; 42(24):2918-2927. PubMed ID: 38833658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.
    Tahara M; Muro K; Hasegawa Y; Chung HC; Lin CC; Keam B; Takahashi K; Cheng JD; Bang YJ
    Cancer Sci; 2018 Mar; 109(3):771-776. PubMed ID: 29284202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.
    Locati LD; Galbiati D; Calareso G; Alfieri S; Singer S; Cavalieri S; Bergamini C; Bossi P; Orlandi E; Resteghini C; Platini F; Granata R; Quattrone P; Mancinelli M; Mariani L; Lo Vullo S; Licitra LF
    Cancer; 2020 Jan; 126(9):1888-1894. PubMed ID: 32031693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
    Saba NF; Chaudhary R; Kirtane K; Marra A; Ekpenyong A; McCook-Veal A; Schmitt NC; Gross JH; Patel MR; Remick J; Bates JE; McDonald MW; Rudra SF; Stokes WA; Biernacki M; Song X; Slebos RJC; Liu Y; Steuer CE; Shin DM; Teng Y; Chung CH
    Clin Cancer Res; 2024 Oct; 30(20):4601-4608. PubMed ID: 39167623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
    Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
    Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y
    Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.